ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfitzenmeyer, P
Right arrow Articles by Camus, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfitzenmeyer, P
Right arrow Articles by Camus, P
Eur Respir J 1996; 9: 1013-1019
Copyright © ERS Journals Ltd 1996

Original Articles

Pleuropulmonary changes induced by ergoline drugs

P Pfitzenmeyer, P Foucher, G Dennewald, B Chevalon, D Debieuvre, P Bensa, F Piard, and P Camus

Classic ergolines, such as bromocriptine, methysergide and ergotamine, can induce chronic pleuropneumonitis. We present the cases of eight patients who developed similar changes whilst on other ergolines. In this retrospective case study spanning 1985-1995, clinical data, radiological material, pulmonary function, bronchoalveolar lavage and histopathology were reviewed. Earlier literature on ergoline-induced pleuropulmonary changes was reviewed. Eight middle-aged to elderly individuals of both sexes developed pleuropulmonary changes during long-term therapy with regular dosages of nicergoline (n = 4), dihydroergocristine (n = 3), or dihydroergotamine (n = 1). Bibasilar pleural thickening with or without pleural effusion was present on chest radiographs and computed tomographic (CT) scans in six cases. Increased erythrocyte sedimentation rate was seen in most. Pure interstitial pneumonitis developed in two patients on dihydroergocristine and was reversible in each. Bronchoalveolar lavage was performed in four cases and was abnormal in all, but demonstrated no consistent pattern. Most patients exhibited lung restriction. The outcome was favourable showing slow improvement in all cases following discontinuation of the ergoline. Slight residual pleural thickening was seen in five out of the six cases with pleural involvement. Nicergoline and dihydroergotamine can induce a syndrome of chronic pleural thickening/effusion that slowly improves after drug withdrawal. Dihydroergocristine can induce reversible interstitial pneumonitis.


This article has been cited by other articles:


Home page
 ChestHome page
N. Hirani, B. Forzley, J. Langridge, C. Bayliff, and D. G. McCormack
Pergolide-induced Pleural Disease in a Patient With Asbestos Exposure
Chest Meeting Abstracts, October 1, 2003; 124(4): 276S - 276.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. K. Danoff, M. E. Grasso, P. B. Terry, and J. A. Flynn
Pleuropulmonary Disease Due to Pergolide Use for Restless Legs Syndrome
Chest, July 1, 2001; 120(1): 313 - 316.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
Ph. Camus, P. Foucher, Ph. Bonniaud, and K. Ask
Drug-induced infiltrative lung disease
Eur. Respir. J., July 1, 2001; 18(32_suppl): 93S - 100s.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Y. Morelock and S. A. Sahn
Drugs and the Pleura
Chest, July 1, 1999; 116(1): 212 - 221.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the European Respiratory Society.